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Novel quinolines carrying pyridine, thienopyridine, isoquino-
line, thiazolidine, thiazole and thiophene moieties as potential 
anticancer agents
As a part of ongoing studies in developing new anticancer 
agents, novel 1,2-dihydropyridine 4, thienopyridine 5, iso-
quinolines 6–20, acrylamide 21, thiazolidine 22, thiazoles 
23–29 and thiophenes 33–35 bearing a biologically active 
quinoline nucleus were synthesized. The structure of newly 
synthesized compounds was confirmed on the basis of ele-
mental analyses and spectral data. All the newly synthesiz ed 
compounds were evaluated for their cytotoxic activity against 
the breast cancer cell line MCF7. 2,3-Dihydrothiazole-5-car-
boxamides 27, 25, 4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxamide (34), 1,2-dihydroisoquinoline-7-carbonitrile (7), 
5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbox-
amide (35), 1,2-dihydroisoquinoline-7-carbonitrile (6), 2-cy-
ano-3-(dimethylamino)-N-(quinolin-3-yl)acrylamide (21), 
1,2-dihydroisoquinoline-7-carbonitriles (11) and (8) exhibited 
higher activity (IC50 values of 27–45 μmol L–1) compared to 
doxorubicin (IC50 47.9 μmol L–1). LQ quinolin-3-yl)-1,2-dihy-
droisoquinoline-7-carbonitrile (12), 2-thioxo-2,3-dihydrothi-
azole-5-carboxamide (28) and quinolin-3-yl)-1,2-dihydroiso-
quinoline-7-carbonitrile (15) show activity comparable to 
doxorubicin, while (quinolin-3-yl)-1,2-dihydroisoquinoline-
7-carbonitrile (9), 2,3-dihydrothiazole-5-carboxamide (24), 
thieno [3,4-c] pyridine-4(5H)-one (5), cyclopenta[b]thio-
phene-3-carboxamide (33) and (quinolin-3-yl)-6-stryl-1,2-
dihydroisoquinoline-7-carbonitrile (10) exhibited moderate 
activity, lower than doxorubicin.
Keywords: quinolines, pyridine, thienopyridine, isoquino-
line, acrylamide, thiazole, thiophene, anticancer activity
Cancer is one of the most critical health issues and is considered the second leading 
cause of death worldwide, just after circulatory diseases. Despite the availability of im-
proved drugs including targeted cancer therapies, the worldwide cancer burden is ex-
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to the World Health Organization (WHO), unless further preventive measures are put into 
practice (1). Quinoline scaffold plays an important role in anticancer drug development 
since their derivatives have shown excellent results through different mechanisms of ac-
tion such as growth inhibition by cell cycle arrest, apoptosis, inhibition of angiogenesis, 
disruption of cell migration and modulation of nuclear receptor responsiveness. The anti-
cancer potential of several of these derivatives has been demonstrated on various cancer 
cell lines. In addition, many of quinoline derivatives are useful in diverse applications 
including pharmaceuticals and are today available as drugs (2). Therefore there is an ur-
gent need to develop new classes of chemotherapeutic agents with different mechanisms 
of action to treat cancer (3). It has been reported that designing a single molecule with more 
than one pharmacophore with different modes of action could be beneficial for the treat-
ment of cancer (4), as well as for reducing unwanted side effects (5). Many quinolines, di-
hydropyridines, thienopyridines, isoquinolines, acrylamides, thiazolidines, thiazoles and 
thiophenes were found to possess antineoplastic activity (6–11). Although the antineoplas-
tic activity of these quinolines was attributed to intercalating binding to DNA, there were 
additional advantages of quinolines that interact with DNA, with a low association con-
stant. The corresponding significant increase in the amount of free drug at equilibrium may 
have an important effect upon the distribution and hence the spectrum of activity and ac­
ces sibility of these molecules to solid tumors (12, 13). On the other hand, a number of quino-
line derivatives were reported to reverse tumor cell multidrug resistance (14, 15). Recently, 
it has been demonstrated that 10 μmol L–1 chloroquine significantly increases cancer cell 
killing effects (4, 16). Several chloroquinolines (CQ) known as antimalarial  drugs, such as 
N1-(7-chloroquinolin-4-yl)-N2,N2-diethylethane-1,2-diamine (I), N1,N1-diethyl-N2­(7­fluoro-
quinolin-4-yl)ethane-1,2-diamine (II), N­butyl­7­fluoroquinolin­4­amine (III), N4-(7-chlo-
Fig. 1. Chemical structures of quinolines reported for anticancer activity:
I  – N1-(7-chloroquinolin-4-yl)-N2,N2-diethylethane-1,2-diamine
II  – N1,N1-diethyl-N2­(7­fluoroquinolin­4­yl)ethane­1,2­diamine
III  – N­butyl­7­fluoroquinolin­4­amine
IV  – N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine
V  – N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
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roquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine (IV) and N4-(6-metho xyquinolin-8-yl)
pentane-1,4-diamine (primaquine, PQ, V) (Fig. 1) have been examined as cytotoxic agents 
against the MCF­7 breast cancer cell line. Some of these compounds were very effective 
(17). It has been reported that CQ and its analogs have a unique property of being accumu-
lated in the lysosomes, raising intralysosomal pH, and resulting in enhancement of cell 
killing by cancer therapeutic agents in a variety of different tumors (18). It is well known 
that many 2-pyridone derivatives revealed diverse biological activities such as anticancer 
(19), cardiotonic (20), and potential HIV­1 specific reverse transcriptase inhibiting (21). In 
view of the above mentioned findings and as a part of our research efforts to explore 
novel anticancer heterocyclic compounds (22–28), we have synthesized a new series of 
quinoline derivatives carrying a number of biologically active moieties as analogues to 
compounds I–V (Fig. 1).
EXPERIMENTAL
Melting points were uncorrected and determined in an open capillary on a Gallen 
Kamp melting point apparatus (Sanyo Gallen Kamp, UK). Precoated silica gel plates 
(Kieselgel 0.25 mm, 60 F254, Merck, Germany) were used for thin layer chromatography. 
A developing solvent system of chloroform/methanol (8:2) was used and the spots were 
detected by UV light. IR spectra (KBr disc) were recorded using an FT-IR spectrophotom-
eter (Perkin Elmer, USA). 1H NMR spectra were scanned on a NMR spectrophotometer 
(Bruker AXS Inc., Switzerland) operating at 500 MHz for 1H- and 125.76 MHz for 13C. 
Chemical shifts are expressed in d-values (ppm) relative to TMS as an internal standard, 
using DMSO-d6 as a solvent. Elemental analyses were done on a model 2400 CHNSO ana-
lyzer (Perkin Elmer, USA). All the values were within ± 0.4 % of the theoretical values. All 
reagents used were of analytical grade. The starting material 3-aminoquinoline was pur-
chased from Sigma (USA) and was directly used for the preparation of target compounds.
Syntheses 
2-Cyano-N-(quinolin-3-yl)acetamide (1). – A mixture of quinolin-3-amine (1.44 g, 0.01 
mol) and ethyl cyanoacetate (1.13 g, 0.01 mol) was fused at 220 °C for 2 h. The reaction 
mixture was cooled and the obtained product was crystallized from ethanol to give 1.
4,6-Dimethyl-2-oxo-1-(quinolin-3-yl)-1,2-dihydropyridine-3-carbonitrile (4). – A mixture of 
compound 1 (2.1 g, 0.01 mol) and acetylacetone (5 mL) containing piperidine (0.5 mL) was 
fused for 6 h. The reaction mixture was cooled and the obtained solid was recrystallized 
from dioxane to give 4.
3-Amino-6-methyl-5-(quinolin-3-yl)thieno[3,4-c]pyridine-4(5H)-one (5). – A mixture of 4 
(2.75 g, 0.01 mol) and elemental sulfur (0.32 g, 0.01 mol) in absolute ethanol (30 mL) contain-
ing 3 drops of triethylamine was refluxed for 8 h. The obtained solid was crystallized from 
dioxane to give 5.
8-Amino-3-methyl-1-oxo-6-phenyl-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile 
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bonitrile (9), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-stryl-1,2-dihydroisoquinoline-7-carbonitrile 









7-carbonitrile (18), 8-amino-6-(4-methoxynaphthalen-1-yl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1, 
2-dihydroisoquinoline-7-carbonitrile (19), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-(thiophen-2-
yl)-1,2-dihydroisoquinoline-7-carbonitrile (20). General procedure. – A mixture of 4 (2.75 g, 0.01 
mol) and the respective benzylidenemalononitrile (0.01 mol) in ethanol (20 mL) containing 
a catalytic amount of piperidine (0.5 mL) was refluxed for 6 h. The obtained solid was filtered 
and crystallized from dioxane to give 6–20, respectively (Scheme 1, Table I). 
2-Cyano-3-(dimethylamino)-N-(quinolin-3-yl)acrylamide (21). – Dimethylformamide-di-
methylacetal (1.19 g, 0.01 mol) was added to a solution of 1 (2.11g, 0.01 mol) in dry xylene 
(20 mL). The reaction mixture was refluxed for 8 h, cooled and the obtained solid was re-
crystallized from ethanol to give 21.
2-(4-Oxothiazolidin-2-ylidene)-N-(quinolin-3-yl) acetamide (22). – A mixture of 1 (2.11 g, 
0.01 mol) and 2­sulfanylacetic acid (0.92 g, 0.01 mol) in dry pyridine (10 mL) was refluxed 
for 18 h. The reaction mixture was cooled and poured into ice/water. The obtained solid 
was recrystallized from acetic acid to give 22.
4-Amino-3-phenyl-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothiazole-5-carboxamide (23), 






General procedure. – To a suspension of 1 (2.11 g, 0.01 mol) in absolute ethanol (20 mL), 
finely divided sulfur (0.32 g, 0.01 mol), 3 drops of triethylamine, aryl isothiocyanate (0.01 
mol) and DMF (10 mL) were added. The reaction mixture was stirred at 60 °C for 6 h, then 
left to cool at room temperature. The separated product was filtered, washed with ethanol, 
dried and crystallized from DMF/ethanol (2:1) to give 23–29, respectively. 
2-Amino-N-(quinolin-3-yl)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide (33), 
2-amino-N-(quinolin-3-yl)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide (34), 2-amino-N-
(quinolin-3-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b] thiophene-3-carboxamide (35). General proce-
dure. – To a solution of 1 (2.11 g, 0.01 mol) in absolute ethanol (30 mL), morpholine (1 mL), 
cyclopentanone or cyclohexanone and/or cycloheptanone (0.01 mol) and sulfur (0.32 g, 0.01 
mol) were added. The reaction mixture was refluxed for 8 h. The separated product was 
filtered, dried and crystallized from dioxane to give 33–35, respectively. 
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1 C12H9N3O (211.22) 220.4 92 68.24/68.51 4.29/4.08 19.89/19.59
4 C17H13N3O (275.30) 278.7 86 74.17/74.46 4.76/4.44 15.26/15.51
5 C17H13N3OS (307.37) 199.9 68 66.43/66.64 4.26/4.51 13.67/13.39
6 C26H18N4O (402.45) 147.2 81 77.59/77.27 4.51/4.19 13.92/13.65
7 C27H20N4O (416.47) 97.7 77 77.87/77.56 4.84/4.59 13.45/13.24
8 C26H18N4O2 (418.45) 269.9 83 74.63/74.31 4.34/4.12 13.39/13.11
9 C27H20N4O2 (432.47) 119.8 79 74.98/74.63 4.66/4.29 12.95/13.18
10 C28H20N4O (428.48) 245.2 68 78.49/78.27 4.70/4.43 13.08/13.36
11 C26H17N4O (436.89) 156.7 78 71.48/71.26 3.92/3.65 12.82/12.49
12 C26H17ClN4O (436.89) 288.8 68 71.48/71.16 3.92/3.63 12.82/13.11
13 C28H23N5O (445.52) 281.8 63 75.49/75.20 5.20/5.01 15.72/15.38
14 C27H18N4O3 (446.46) 318.0 74 72.64/72.33 4.06/4.27 12.55/12.29
15 C26H17N5O3 (447.44) 150.8 67 69.79/69.52 3.83/3.48 15.65/15.41
16 C26H17N5O3 (447.44) 234.0 77 69.79/69.43 3.83/3.50 15.65/15.34
17 C26H16Cl2N4O (471.34) 174.2 78 69.25/69.59 3.42/3.12 11.89/12.24
18 C31H22N4O2 (482.53) 215.9 59 77.16/77.52 4.60/4.33 11.61/11.30
19 C31H22N4O2 (482.53) 344.9 63 77.16/77.46 4.60/4.91 11.61/11.35
20 C24H16N5OS (408.48) 128.9 74 70.57/70.88 3.95/3.76 13.72/13.42
21 C15H14N4O (266.30) 187.9 85 67.65/67.36 5.30/5.10 21.04/21.31
22 C16H11N3O2S (285.32) 296.6 78 58.93/58.66 3.89/3.60 14.73/14.39
23 C19H14N4OS2 (378.47) 97.0 88 60.30/60.06 3.73/3.48 14.80/14.52
24 C20H16N4OS2 (392.50) 112.3 85 61.20/61.49 4.11/4.41 14.27/14.53
25 C19H13FN4OS2 (396.46) 263.1 71 57.56/57.32 3.31/3.07 14.13/14.40
26 C20H16N4O2S2 (408.50) 275.4 78 58.80/58.54 3.95/3.63 13.72/13.45
27 C19H13N3O3S2 (423.47) 169.9 70 53.89/53.55 3.09/3.37 16.45/16.16
28 C19H13BrN4OS2 (457.37) 148.6 80 49.90/49.61 2.86/2.48 12.25/12.01
29 C19H13IN4OS2 (504.37) 138.7 79 45.25/45.51 2.60/2.32 11.11/11.40
33 C17H15N3OS (309.39) 230.0 66 66.00/66.29 4.89/4.57 13.58/13.88
34 C18H17N3OS (323.41) 197.3 69 66.85/66.49 5.30/5.04 12.99/12.66
35 C19H19N3OS (337.44) 161.1 61 67.63/67.37 5.68/5.35 12.45/12.19
Physicochemical and spectral data are given in Tables I and II and synthetic pathways 
in Schemes 1 and 2.
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1 3260 (NH), 3091 (CH arom.), 
2957, 2927 (CH aliph.),  
2201 (C≡N), 1700 (C=O),  
1617 (C=N)
4.0 (s, 2H, CH2), 7.5, 8.6 (2s, 2H, 2CH quinoline), 7.6–7.9 
(m, 4H, Ar-H), 10.8 (s, 1H, NH, D2O-exchangeable)





4 3062 (CH arom.), 2937, 2870 
(CH aliph.), 2218 (C≡N),  
1658 (C=O), 1585 (C=N)
2.0 (s, 6H, 2CH3), 6.5 (s, 1H, CH pyridone), 7.3, 8.8 
(2s, 2H, 2CH quinoline), 7.5–8.1 (m, 4H, Ar-H) 
20.7, 21.7, 100.0, 109.3, 115.6, 127.3, 127.5, 128.4, 128.8, 




5 3406, 3326 (NH2), 2976, 2836 
(CH aliph.), 1657 (C=O),  
1611 (C=N)
1.6 (s, 1H, CH3), 5.1 (s, 1H, CH pyridone), 6.6 (s, 1H, CH 
thiophene), 7.1, 8.6 (2s, 2H, 2CH quinoline), 7.2–8.3 (m, 
6H, Ar-H + NH2)
21.7, 105.4, 123.6, 124.1, 126.2 (2), 127.1 (2), 128.6, 131.8, 




6 3405, 3386 (NH2), 3066 
(CH arom.), 2910, 2861  
(CH aliph.), 2184 (C≡N),  
1695 (C=O), 1586 (C=N)
1.7 (s, 3H, CH3), 5.2 (s, 2H, NH2, D2O-exchangeable), 6.4 
(s, 1H, CH pyridone), 7.1, 8.6 (2s, 2H, 2CH quinoline), 
7.2–8.3 (m, 10H, Ar-H) 
21.6, 95.2, 101.8, 114.2, 116.7, 116.9, 122.8, 123.6, 124.7, 
127.5, 127.9, 128.6 (2), 128.9, 129.1, 129.2 (2), 129.4, 135.1 (2), 




7 3310, 3205 (NH2), 3100 
(CH arom.), 2920, 2863  
(CH aliph.), 2184 (C≡N),  
1689 (C=O), 1599 (C=N)
1.3 (s, 3H, CH3), 2.3 (s, 3H, CH3 tolyl), 6.0 (s, 2H, NH2, 
D2O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.0, 8.6 (2s, 
2H, 2CH quinoline), 7.2–8.4 (m, 9H, Ar-H) 
18.4, 24.0, 97.4, 100.4, 116.6, 116.8, 117.9, 125.2 (2), 127.4, 
127.9, 129.1 (2), 128.5, 128.8, 129.3 (2), 129.7, 132.3, 135.8, 




8 3431 (br, OH), 3371, 3312 
(NH2), 3069 (CH arom.), 
2927, 2863 (CH aliph.),  
2217 (C≡N), 1661 (C=O),  
1585 (C=N)
2.0 (s, 3H, CH3), 6.0 (s, 2H, NH2, D2O-exchangeable), 6.5 
(s, 1H, CH pyridone), 7.0, 8.8 (2s, 2H, 2CH quinoline), 
7.7–8.5 (m, 9H, Ar-H), 9.0 (s, 1H, OH, D2O-exchangeable)
20.7, 92.4, 100.0, 115.6, 116.8 (2), 118.1, 118.3, 123.7, 126.1, 
127.3, 127.5 (2), 128.4 (2), 128.8 (2), 130.7, 135.1 (2), 139.6, 




9 3378, 3296 (NH2), 3061 
(CH arom.), 2971, 2819  
(CH aliph.), 2191 (C≡N),  
1676 (C=O), 1599 (C=N)
1.6 (s, 3H, CH3), 3.8 (s, 3H, OCH3), 6.2 (s, 2H, NH2, 
D2O-exchangeable), 6.3 (s, 1H, CH pyridone), 6.9, 6.8 (2s, 
2H, 2CH quinoline), 7.1–8.4 (m, 9H, Ar-H) 
18.4, 56.0, 96.5, 99.9, 113.7 (2), 114.4, 115.1, 116.0, 125.2, 
127.3, 127.5, 127.7, 128.1, 128.4, 128.8 (2), 129.6, 130.0, 135.6, 




10 3391, 3286 (NH2), 3100 
(CH arom.), 2976, 2912  
(CH aliph.), 2218 (C≡N),  
1663 (C=O), 1609 (C=N)
1.5 (s, 3H, CH3), 6.2 (s, 2H, NH2, D2O-exchangeable), 6.4 
(s, 1H, CH pyridone), 6.8, 7.3 (2d, 2H, CH=CH, J = 7.4 Hz), 
7.4, 8.8 (2s, 2H, 2CH quinoline), 7.5–8.5 (m, 10H, Ar-H) 
20.7, 97.6, 100.0, 109.3, 115.6 (2), 123.6, 123.8, 124.1, 124.4, 
125.0, 126.8, 127.1 (2), 127.6 (2), 128.3 (2), 128.9 (2), 135.1 (2), 
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11 3398, 3334 (NH2), 3077 
(CH arom.), 2929, 2845  
(CH aliph.), 2219 (C≡N),  
1653 (C=O), 1576 (C=N),  
754 (C-Cl)
1.5 (s, 3H, CH3), 5.9 (s, 2H, NH2, D2O- exchangeable), 6.5 
(s, 1H, CH pyridone), 7.2, 8.8 (2s, 2H, 2CH quinoline), 
7.4–8.1 (m, 9H, Ar-H) 
20.7, 88.1, 100.1, 115.6 (2), 115.9, 126.9 (2), 127.3, 127.5, 127.7, 
128.4, 128.8, 129.3, 129.7 (2), 130.0, 131.3, 133.2, 135.1 (2), 




12 3265, 3212 (NH2), 3091 
(CH arom.), 2976, 2844  
(CH aliph.), 2218 (C≡N),  
1658 (C=O), 1587 (C=N),  
818 (C-Cl)
1.6 (s, 3H, CH3), 4.4 (s, 2H, NH2, D2O-exchangeable), 6.5 
(s, 1H, CH pyridone), 7.0, 8.8 (2s, 2H, 2CH quinoline), 
7.2–8.3 (m, 9H, Ar-H) 
22.1, 85.2, 101.6, 115.8, 116.0 (2), 122.7, 123.4, 124.8, 126.1, 
128.6, 128.7, 129.8 (2), 130.3 (2), 131.6, 131.9, 134.3 (2), 136.1, 




13 3406, 3399 (NH2), 3047 
(CH arom.), 2221 (C≡N), 
1654 (C=O), 1592 (C=N)
2.0 (s, 3H, CH3), 2.9 (s, 6H, N(CH3)2), 6.0 (s, 2H, NH2, 
D2O-exchangeable), 6.1 (s, 1H, CH pyridone), 7.0, 8.6 (2s, 
2H, 2CH quinoline), 7.2–8.2 (m, 9H, Ar-H) 
21.9, 40.1 (2), 95.5, 102.6, 111.7 (2), 112.0, 115.4, 116.0, 122.2, 
127.3 (2), 127.4 (2), 128.4, 128.8 (2), 129.8, 130.7, 135.2, 141.3 




14 3368, 3276 (NH2), 3050 
(CH arom.), 2921, 2898  
(CH aliph.), 2215 (C≡N),  
1659 (C=O), 1597 (C=N)
2.0 (s, 3H, CH3), 6.0 (s, 2H, NH2, D2O-exchangeable), 
6.1 (s, 1H, CH pyridone), 6.5 (s, 2H, O-CH2-O), 7.0, 8.6 
(2s, 2H, 2CH quinoline), 7.2–8.2 (m, 8H, Ar-H) 
20.7, 94.3, 100.8, 101.6, 109.3, 116.8 (2), 118.3, 118.7, 121.9, 
122.4, 124.6, 127.3, 127.5, 128.4, 128.8, 130.7 (2), 135.1 (2), 




15 3431, 3291 (NH2), 3100 
(CH arom.), 2946, 2908  
(CH aliph.), 2200 (C≡N), 
1653 (C=O), 1595 (C=N), 
1568, 1361 (NO2)
1.6 (s, 3H, CH3), 5.8 (s, 2H, NH2, D2O-exchangeable), 6.5 
(s, 1H, CH pyridone), 7.5, 8.8 (2s, 2H, 2CH quinoline), 
7.6–8.2 (m, 8H, Ar-H) 
20.7, 95.7, 100.0, 109.3, 115.6 (2), 122.1, 123.3 (2), 127.3 (2), 
127.5, 128.4, 128.7, 130.4, 130.7, 130.8, 135.1 (2), 140.8 (2), 




16 3386, 3351 (NH2), 3081 
(CH arom.), 2917, 2866  
(CH aliph.), 2189 (C≡N),  
1654 (C=O), 1585 (C=N), 
1518, 1343 (NO2)
1.6 (s, 3H, CH3), 6.0 (s, 2H, NH2, D2O-exchangeable), 6.5 
(s, 1H, CH pyridone), 7.2, 8.8 (2s, 2H, 2CH quinoline), 
7.4–8.5 (m, 9H, Ar-H) 
18.5, 94.6, 100.0, 109.3, 115.6 (2), 123.6 (2), 124.2 (2), 127.3, 
127.5, 128.4, 128.7 (2), 130.1, 130.4, 135.1 (2), 142.6, 144.8 




17 3391, 3317 (NH2), 3100 
(CH arom.), 2929, 2810  
(CH aliph.), 2216 (C≡N),  
1660 (C=O), 1585 (C=N),  
751 (C-Cl)
1.5 (s, 3H, CH3), 6.0 (s, 2H, NH2, D2O-exchangeable), 6.9 
(s, 1H, CH pyridone), 7.3, 8.8 (2s, 2H, 2CH quinoline), 
7.4–8.5 (m, 8H, Ar-H) 
18.5, 93.6, 100.0, 109.3, 115.6 (2), 127.3 (2), 127.5 (2), 128.1, 
128.4, 128.7, 129.4, 130.7, 130.8, 132.2 (2), 135.7 (2), 142.1 (2), 




18 3436, 3421 (NH2), 3058 
(CH arom.), 2934, 2836  
(CH aliph.), 2213 (C≡N),  
1654 (C=O), 1578 (C=N)
2.0 (s, 3H, CH3), 3.8 (s, 3H, OCH3), 6.0 (s, 2H, NH2, 
D2O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.2, 8.8 
(2s, 2H, 2CH quinoline), 7.4–8.4 (m, 11H, Ar-H) 
18.5, 56.0, 98.1, 100.0, 113.7, 115.6, 116.1, 122.9, 123.9 (2), 
127.1, 127.3, 127.5, 127.6, 128.4 (2), 128.7 (2), 130.5 (2), 130.7 
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19 3404, 3395 (NH2), 3100 
(CH arom.), 2961, 2846  
(CH aliph.), 2214 (C≡N),  
1653 (C=O), 1589 (C=N)
1.8 (s, 3H, CH3), 4.0 (s, 3H, OCH3), 6.0 (s, 2H, NH2, 
D2O-exchangeable), 6.5 (s, 1H, CH pyridone), 7.0, 8.5 
(2s, 2H, 2CH quinoline), 7.2–8.3 (m, 11H, Ar-H) 
20.7, 57.4, 92.1, 100.0, 109.3, 113.2, 115.6, 117.8, 119.9, 122.8, 
123.6, 124.4, 124.8, 124.9, 125.0, 126.3, 127.3, 127.5, 128.4, 





20 3401, 3381 (NH2), 3066 
(CH arom.), 2972, 2818  
(CH aliph.), 2190 (C≡N),  
1688 (C=O), 1508 (C=N)
1.8 (s, 3H, CH3), 5.9 (s, 2H, NH2, D2O-exchangeable), 6.7 
(s, 1H, CH pyridone), 7.0, 8.6 (2s, 2H, 2CH quinoline), 
7.2–8.2 (m, 8H, Ar-H) 
18.5, 97.1, 102.8, 109.3, 115.6 (2), 120.1, 127.3 (2), 127.5 (2), 





21 3287 (NH), 3079 (CH arom.), 
2936, 2871 (CH aliph.),  
2224 (C≡N), 1688 (C=O),  
1593 (C=N)
2.6 (s, 6H, 2CH3), 7.0- 8.3 (m, 4H, Ar-H), 7.5 (s.1H, CH), 
7.3, 8.6 (2s, 2H, 2CH quinoline), 8.9 (s, 1H, NH,  
D2O-exchangeable)
40.0 (2), 90.0, 118.8, 125.6 (2), 127.2, 127.5, 128.2, 130.2, 




22 3159 (NH), 3100 (CH arom.), 
2966, 2871 (CH aliph.),  
1705, 1679 (2 C=O),  
1581 (C=N)
3.7 (s, 2H, CH2CO), 5.8 (s, 1H, CH), 7.5, 8.8 (2s, 2H, 2CH 
quinoline), 7.6–8.0 (m, 4H, Ar-H), 10.3 (s, 1H, NH, 
D2O-exchangeable), 11.6 (s, 1H, NH, thiazolidine, 
D2O-exchangeable)
32.1, 91.9, 120.7, 126.9, 127.3, 127.5, 128.0, 128.4, 133.5, 143.7, 




23 3410, 3286 (NH, NH2), 
3066 (CH arom.), 1686 
(C=O), 1577 (C=N),  
1234 (C=S)
4.5 (s, 2H, NH2, D2O-exchangeable), 6.9, 8.7 (2s, 2H, 2CH 
quinoline), 7.1–8.2 (m, 9H, Ar-H), 11.0 (s, 1H, NH,  
D2O-exchangeable)
81.9, 123.1 (2), 124.3, 124.5, 127.4 (2), 127.7, 128.1, 129.0, 




24 3379, 3234 (NH, NH2), 
3057 (CH arom.), 2919,  
2886 (CH aliph.), 1669 (C=O), 
1586 (C=N), 1273 (C=S)
2.3 (s, 3H, CH3), 4.5 (s, 2H, NH2, D2O-exchangeable), 6.9, 
8.6 (2s, 2H, 2CH quinoline), 7.1–8.2 (m, 8H, Ar-H), 10.9  
(s, 1H, NH, D2O-exchangeable)
20.8, 81.7, 121.6, 122.9, 127.6, 18 (2), 128.3, 128.5, 128.8, 




25 3367, 3286 (NH, NH2), 
3100 (CH arom.), 1667 (C=O), 
1589 (C=N), 1224 (C=S)
4.5 (s, 1H, NH2, D2O-exchangeable), 7.1, 8.6 (2s, 2H, 2CH 
quinoline), 7.4–8.1 (m, 8H, Ar-H), 9.7 (s, 1H, NH,  
D2O-exchangeable)
82.0, 117.0 (2), 123.7, 126.9, 127.5, 127.7, 127.9 (2), 128.4, 




26 3415, 3339 (NH, NH2), 
3071 (CH arom.), 2961,  
2831 (CH aliph.), 1683 (C=O), 
1586 (C=N), 1234 (C=S)
3.8 (s, 3H, OCH3), 4.5 (s, 2H, NH2, D2O-exchangeable), 
7.1, 8.6 (2s, 2H, 2CH quinoline), 7.3–8.0 (m, 8H, Ar-H), 9.7 
(s, 1H, NH, D2O-exchangeable)
55.4, 81.9, 115.3 (2), 123.5, 126.9, 127.2, 127.5, 127.7, 127.8 (2), 




27 3286, 3212 (NH, NH2), 
3068 (CH arom.),  
1658 (C=O), 1591 (C=N),  
1202 (C=S)
4.5 (s, 2H, NH2, D2O-exchangeable), 7.0, 8.6 (2s, 2H, 2CH 
quinoline), 7.4–8.2 (m, 8H, Ar-H), 11.6 (s, 1H, NH,  
D2O-exchangeable)
86.3, 121.0 (2), 122.8, 123.5, 124.5, 127.3, 128.7 (2), 130.5 (2), 
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In vitro antitumor activity
The cytotoxic activity in vitro of the newly synthesized compounds was evaluated 
using the sulforhodamine B stain (SRB) assay and the method of Skehan (29). The human 
breast cancer cell line (obtained from the National Cancer Institute, Cairo, Egypt) was 
maintained at 37 °C in 5 % CO2 as sub­confluent monolayers in 80 cm3 culture flasks (Nun-
clon, Sigma, USA) and was subcultured once or twice weekly in Dulbecco’s modification 
of Eagle’s medium (Flow, Sigma, USA) supplemented with 5 % heat-inactivated fetal calf 
serum (FCS) and 1 mmol L–1 L-glutamine (Sigma). During the experiments, 50 μg mL–1 
gentamicin (Sigma) was added to the culture medium. Passage levels were in the range of 
5–20 according to the original receipt. Cells were harvested from exponential phase cul-
tures by trypsinisation, counted and plated in 96­well flat bottomed microliter plates 
(Greiner Labortechnik, Germany) (100 μL cell suspension containing 104 cells per well). 
Following plating and a 24-h recovery to allow cells to resume exponential growth, 100 μL 
culture medium or culture medium containing the drug were added to the wells. Test 
compounds were dissolved in DMSO as a 0.1 μmol L–1 stock solution (the final concentra-
tion of DMSO in culture medium was less than 0.1 %). Different concentrations of each test 
compound (5, 12, 25 and 50 μmol L–1) were obtained by dilution with phosphate buffered 
saline (PBS) then added to the cell monolayer. Triplicate wells were prepared for each in-
dividual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C and 
28 3310, 3286 (NH, NH2), 
3100 (CH arom.), 1691 (C=O), 
1589 (C=N), 1261 (C=S)
4.5 (s, 2H, NH2, D2O-exchangeable), 7.0, 8.5 (2s, 2H, 2CH 
quinoline), 7.2–8.2 (m, 8H, Ar-H), 11.1 (s, 1H, NH,  
D2O-exchangeable)
91.2, 118.6, 123.5, 124.5, 125.5, 127.2, 128.2, 128.4 (2), 130.4, 




29 3229, 3186 (NH, NH2), 
3081 (CH arom.), 1686 (C=O), 
1587 (C=N), 1247 (C=S)
4.5 (s, 2H, NH2, D2O-exchangeable), 7.0, 8.5 (2s, 2H, 2CH 
quinoline), 7.1–8.2 (m, 8H, Ar-H), 11.1 (s, 1H, NH,  
D2O-exchangeable)
88.7, 95.2, 125.7, 127.2, 127.5, 128.2, 128.6 (2), 128.6, 130.8, 




33 3406, 3381 (NH, NH2), 
3051 (CH arom.), 2936,  
2847 (CH aliph.), 1680 (C=O), 
1590 (C=N)
2.3–3.0 (m, 6H, 3CH2 cyclo), 7.1, 8.6 (2s, 2H, 2CH 
quinoline), 7.2–8.4 (m, 6H, Ar-H + NH2), 11.8 (s, 1H, NH, 
D2O-exchangeable)
22.6, 28.8, 37.7, 116.6, 125.1, 125.5 (2), 125.9, 126.4, 127.9, 




34 3247, 3176 (NH, NH2), 
3091 (CH arom.), 2926,  
2853 (CH aliph.), 1657 (C=O), 
1610 (C=N)
1.3–2.7 (m, 8H, 4CH2 cyclo), 7.2, 8.6 (2s, 2H, 2CH 
quinoline), 7.7–8.2 (m, 6H, Ar-H + NH2), 10.5 (s, 1H, NH, 
D2O-exchangeable)
22.0, 22.9, 24.0, 25.3, 110.2, 120.0, 126.7 (2), 127.7, 128.1, 




35 3420, 3381 (NH, NH2), 
3100 (CH arom.), 2927,  
2861 (CH aliph.), 1676 (C=O), 
1599 (C=N)
1.2–2.6 (m, 10H, 5CH2 cyclo), 7.0, 8.6 (2s, 2H, 2CH 
quinoline), 7.4–7.9 (m, 6H, Ar-H + NH2), 10.7 (s, 1H, NH, 
D2O-exchangeable)
22.6, 27.4, 30.2, 30.8, 31.4, 116.5, 122.6, 124.1 (2), 125.7, 
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in an atmosphere of 5 % CO2. Forty­eight hours after drug addition, cells were fixed with 
50 % trichloroacetic acid at 4 °C (50 μL per well) for 1 h, washed with 1 % acetic acid and 
stained for 30 min with 50 μL of 0.4 % (m/V) sulphorhodamine (SRB) dissolved in 1 % ace-
Table III. In vitro cytotoxic activity of the newly synthesized compounds 1, 4–29, 33–35 against the human 


































































































NA – no activity observed under experimental conditions.
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tic acid. Excess unbound dye was removed by four washes with 1 % acetic acid and the 
attached stain was recovered with Tris­EDTA buffer. Colour intensity was measured using 
an enzyme-linked immunosorbent assay ELISA reader (BMG LABTECH GmbH, Germa-
ny). Absorbance was measured at 510 nm. The relation between the surviving fraction and 
drug concentration was plotted to get the survival curve for the breast cancer cell line 
(MCF7) after specified time (29). The molar concentration required for 5 % inhibition of cell 
viability (IC50) was preliminarily calculated from the constructed dose-response curve 




Schemes 1 and 2 outline the synthetic pathways used to obtain compounds 1–35. The 
solvent-free reaction of aryl amines with ethyl cyanoacetate is well known as one of the 
most widely used synthetic methods. Thermal fusion of 3-aminoquinoline with ethyl cya-
noacetate at 220 °C afforded the corresponding 2­cyano­N-(quinolin-N-3-yl)acetamide (1). 
The structure of novel compounds was established on the basis of elemental analysis and 
spectral data. IR spectrum of compound 1 showed bands at 3260 cm–1 NH, and 2201 cm–1 
C≡N, while 1H-NMR spectrum revealed a singlet at 4.0 ppm assigned to the CH2 group. In 
addition, the structure of compound 1 was confirmed through X­ray crystallography (30) 
(Figs. 2 and 3).
The present study was aimed to prepare novel quinolone derivatives using cyano-
acetamide 1 as strategic starting material. Thus, interaction of compound 1 with acetyl-
acetone furnished the corresponding 4,6-dimethyl-2-oxo-1-(quinolin-3-yl)-1,2-dihydro-
pyridine-3-carbonitrile 4. It can be postulated that the reaction initially proceeded via a 
nucleophilic attack to form Michael adduct 2 which in turn cyclized to product 3. Elimination 
of two molecules of water gave 1,2-dihydropyridine 4. IR spectrum of 4 showed the absence 
of NH2 group and the presence of bands at 2937 and 2870 cm–1 (CH aliphatic), 2218 cm–1 
(C≡N), and 1658 cm–1 (C=O). Its 1H NMR spectrum displayed the following signals: 2.0 ppm 
for 2CH3 and 6.5 ppm for pyridinone CH. Interaction of 4 with elemental sulfur in ethanolic 
triethylamine furnished the corresponding thienopyridine derivative 5. Its IR spectrum 
revealed characteristic bands at 3406, 3326 (NH2), 1657 cm–1 (C=O), and 1611 cm–1 (C=N). 1H 
Fig. 2. Oak Ridge thermal ellipsoid plot (ORTEP) diagram of the title compound 1 drawn at 40 % el-
lipsoids for non-hydrogen atoms.
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NMR spectrum showed signals at 1.6 ppm for CH3, 5.1 ppm for pyridinone CH, and 6.6 ppm 
for thiophene CH. 13C NMR spectrum revealed a singlet at 161.2 ppm assigned to C=O. 
Application of Michael addition of 4 to benzylidinemalononitriles in absolute ethanol in the 
presence of piperidine yielded the corresponding 1,2-dihydroisoquinoline derivatives 6–20, 
via loss the of HCN molecule (Scheme 1). IR spectra of compounds 6–20 revealed the presence 
of bands for NH2, C≡N, C=O and C=N. 1H NMR spectra of compounds 6–20 exhibited a 
singlet at 6.2–4.4 ppm assigned to the NH2 group. Treatment of 1 with dimethylformamide-
dimethylacetal (DMF-DMA) in dry xylene gave the corresponding enamine derivative 21. 
IR spectrum showed bands at 3287 cm–1 (NH), 2224 cm–1 (C≡N), and 1688 cm–1 (C=O). 1H 
NMR spectrum revealed signals at 2.6 ppm for N(CH3), 7.5 ppm for the CH group and 8.9 
ppm for the NH group. Interaction of compound 1 with 2-sulfanylacetic acid in pyridine 
produced the corresponding thiazolidine derivative 22. Compound 22 was characterized by 
the presence of a strong absorption band at 1705 cm–1 in the IR spectrum specific for the 
thiazolidinone as a proof of cyclization. In the 1H NMR spectrum, it was the presence of a 
singlet equivalent to two protons at 3.7 ppm, representing the C-5 protons of the 
thiazolidinone nucleus. The 13C NMR spectrum of compound 22 showed signals at 174.1 and 
32.1 ppm (C-4 and C-5 in the thiazolidinone nucleus). On the other hand, 4-amino-3-
substituted-N-(quinolin-3-yl)-2-thiox-2,3-dihydrothiazde-5-carboxamides 23–29 were 
obtained by the reaction of 1 with sulfur and aryl isothiocyanate in DMF-EtOH containing 
triethylamine as a catalyst. IR spectra of compounds 23–29 showed bands for the NH, NH2, 
C=O, C=N, C=S groups. 1H NMR spectra revealed a singlet at 4.5 ppm assigned to the NH2 
Fig. 3. Crystal packing of compound 1 showing intermolecular hydrogen bonds as dashed lines.
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group. 13C NMR spectra of compounds 23–29 revealed signals at 189.6–183.9 ppm for C=S 
groups.
Finally, the corresponding thiophene derivatives 33–35 were obtained via the reaction 
of 1 with cyclopentanone or cyclohexanone and/or cycloheptanone and sulfur in a mixture 
of DMF/EtOH containing a catalytic amount of morpholine. The reaction may be explained 
via the intermediates 30–32 (Scheme 2). Their IR spectra revealed bands at 3420–3176 cm–1 
(NH, NH2) and 1680–1657 cm–1 (C=O). 1H NMR spectrum of 33 exhibited signals at 2.3–3.0 
ppm for the 3-cyclopentyl CH2 group. 1H NMR spectrum of 34 showed signals at 1.3–2.7 
ppm for the 4-cyclohexyl CH2 group. 1H NMR spectrum of 35 revealed signals at 1.2–2.6 
ppm corresponding to the 5-cycloheptyl CH2 group.
Schemes 1
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In vitro antitumor activity
The IC50 concentrations are presented in Table III. Most of the synthesized compounds 
showed better cytotoxic activity than doxorubicin (IC50 47.9 μmol L–1) against the MCF7 cell 
line except compounds 1, 4, 18 and 20 (IC50 values: 98–108 μmol L–1). The quinoline deriva-
tive carrying dihydrothiazole with 4-nitrophenyl and thioxo moiety (27), dihydrothiazole 
with 4­fluorophenyl and thioxo moiety (25), tetrahydrobenzothiophene (34), dihydroiso-
quinoline with 4-methylphenyl and carbonitrile moiety (7), tetrahydro-4-H-cyclohepta-
thiophene (35), dihydroisoquinoline with unsubstituted phenyl moiety (6), acrylamide 
moiety (21), dihydroisoquinoline with 2-chlorophenyl moiety (11), dihydroisoquinoline 
Schemes 2
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with 4-hydroxyphenyl moiety (8) with exhibited good cytotoxic activity better than doxo-
rubicin as reference drug (IC50 26.7 to 44.7 μmol L–1). A closer look into the structure activ-
ity relationship indicates that addition of dihydrothiazole with thioxo group at 2-position, 
4-nitrophenyl at 3-position, free amino group at 4-position, dihydrothiazole with thioxo 
group at 2­position, 4­fluorophenyl at 3­position, free amino group at 4­position and 
tetrahydrobenzo[b]thiophene with free amino group at 2-position was proven to be suc-
cessful in the case of compounds 27, 25 and 34, which showed an increase in activity. Also, 
quinolone incorporating tetrahydrobenzo[b]thiophene (34) with IC50 33.1 μmol L–1 exhib-
ited higher activity than cyclopenta[b]thiophene (33) with IC50 66.3 μmol L–1. The presence 
of the cyclohepta[b]thiophene ring in compound (35) (IC50 37.6 μmol L–1) enhanced the 
anti-breast cancer activity more than the corresponding cyclopenta[b]thiophene (33) (IC50 
66.3 μmol L–1). In addition, quinoline bearing dihydroisoquinoline with 4-chlorophenyl 
(12), dihydroisoquinoline with 3-nitrophenyl moiety (15) and dihydrothiazole with 4-bro-
mophenyl moiety (28) were nearly as active as doxorubicin (IC50 51.8 to 53.4 μmol L–1). On 
the other hand, compounds 5, 9, 10, 24 and 33 exhibited moderate activity. Compounds 1, 
4, 18 and 20 were the least active compounds in this series compared to doxorubicin, while 
the remaining compounds revealed no activity.
CONCLUSIONS
The objective of the present study was to synthesize and investigate the anti-breast 
cancer activity of some novel quinoline derivatives bearing biologically active moieties. All 
the synthesized compounds were characterized and evaluated for their anti-breast cancer 
activity and it was found that 4-amino-3-(4-nitrophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-di-
hydrothiazole-5-carboxamide (27), 4­amino­3­(4­fluorophenyl)­N-(quinolin-3-yl)-2-thioxo-2, 
3-dihydrothiazole-5-carboxamide (25), 2-amino-N-(quinolin-3-yl)-4,5,6,7-tetrahydrobenzo[b]
thiophene-3-carboxamide (34), 8-amino-3-methyl-1-oxo-2-(quinolin-3-yl)-6-p-tolyl-1,2-
dihydro isoquinoline-7-carbonitrile (7), 2-amino-N-(quinolin-3-yl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b] thiophene-3-carboxamides (35), 8-amino-3-methyl-1-oxo-6-phenyl-2-(quino-
lin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (6), 2-cyano-3-(di methyl amino)-N-
(quinolin-3-yl)acrylamide (21), 8-amino-6-(2-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-
yl)-1,2-dihydroisoquinoline-7-carbonitrile (11) and 8-amino-6-(4-hydroxyphenyl)-3-methyl-
1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (8) exhibited anti-breast can-
cer activity higher than the positive control doxorubicin. Also, it was found that 
8-amino-6-(4-chlorophenyl)-3-methyl-1-oxo-2-(quinolin-3-yl)-1,2-dihydroisoquinoline-7-
carbonitrile (12), 4-amino-3-(4-bromophenyl)-N-(quinolin-3-yl)-2-thioxo-2,3-dihydrothia-
zole-5-carboxamide (28), and 8-amino-3-methyl-6-(3-nitrophenyl)-1-oxo-2-(quinolin-3-yl)-1, 
2-dihydroisoquinoline-7-carbonitrile (15) are almost as active as doxorubicin. 
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